ECJ opinion may not resolve dual pricing issue
This article was originally published in Scrip
Dual pricing schemes designed to restrict parallel trade are a restriction of competition in the opinion of Verica Trstenjak, advocate general at the European Court of Justice, but this may not resolve a long-running court case involving GlaxoSmithKline and the European Commission.
You may also be interested in...
Patents on Janssen-Cilag's (Johnson & Johnson) anti-epileptic Topamax/Epitomax (topiramate) expired in many European countries on September 25th, and generics companies are launching their own versions quickly.
Local health authorities in Coventry, UK, say it is most unlikely that vaccination with GlaxoSmithKline's Cervarix (human papillomavirus vaccine) was the cause of the death of a 14-year-old schoolgirl on September 28th.
Lilly's Alimta (pemetrexed) has been recommended as a first-line treatment for some patients in England and Wales with non-small cell lung cancer (NSCLC) in binding guidance for the national health service.